Novel C-3N-urea, amide, and carbamate dihydroindazolo[5,4-a] pyrrolo[3,4-c]carbazole analogs as potent TIE-2 and VEGF-R2 dual inhibitors

被引：19

作者：

Becknell, Nadine C. ^{[1
]}

Zulli, Allison L. ^{[1
]}

Angeles, Thelma S. ^{[1
]}

Yang, Shi ^{[1
]}

Albom, Mark S. ^{[1
]}

Aimone, Lisa D. ^{[1
]}

Robinson, Candy ^{[1
]}

Chang, Hong ^{[1
]}

Hudkins, Robert L. ^{[1
]}

机构：

[1] Cephalon Inc, W Chester, PA 19380 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2006年 / 16卷 / 20期

关键词：

antiangiogenenic therapy; anti-tumor; tyrosine kinases; TIE-2; VEGF-R2;

D O I：

10.1016/j.bmcl.2006.07.066

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A novel series of C-3 urea, amide, and carbamate fused dihydroindazolocarbazole (DHI) analogs are reported as highly potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases with excellent cellular potency. Structure-activity relationship (SAR) studies indicate the optimal N-13 alkyl substitutions are n-propyl and i-butyl. The isopropyl carbamate 39 displayed good dual enzyme, cell potency, and rat pharmacokinetic properties for advancement to in vivo evaluation. (c) 2006 Elsevier Ltd. All rights reserved.

引用

收藏

页码：5368 / 5372

页数：5

相关论文

共 22 条

[1] Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization [J].

Asahara, T ;

Chen, DH ;

Takahashi, T ;

Fujikawa, K ;

Kearney, M ;

Magner, M ;

Yancopoulos, GD ;

Isner, JM .

CIRCULATION RESEARCH, 1998, 83 (03) :233-240

[2]

Beebe JS, 2003, CANCER RES, V63, P7301

[3] Angiogenesis in cancer and other diseases [J].

Carmeliet, P ;

Jain, RK .

NATURE, 2000, 407 (6801) :249-257

[4] Angiogenesis modulation in cancer research: Novel clinical approaches [J].

Cristofanilli, M ;

Charnsangavej, C ;

Hortobagyi, GN .

NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (06) :415-426

[5] Anti-angiogenic agents: clinical trial design and therapies in development [J].

Deplanque, G ;

Harris, AL .

EUROPEAN JOURNAL OF CANCER, 2000, 36 (13) :1713-1724

[6] VEGF as a therapeutic target in cancer [J].

Ferrara, N .

ONCOLOGY, 2005, 69 :11-16

[7] Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development [J].

Gale, NW ;

Yancopoulos, GD .

GENES & DEVELOPMENT, 1999, 13 (09) :1055-1066

[8] A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors:: Structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-α]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055 [J].

Gingrich, DE ;

Reddy, DR ;

Iqbal, MA ;

Singh, J ;

Aimone, LD ;

Angeles, TS ;

Albom, M ;

Yang, S ;

Ator, MA ;

Meyer, SL ;

Robinson, C ;

Ruggeri, BA ;

Dionne, CA ;

Vaught, JL ;

Mallamo, JP ;

Hudkins, RL .

JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (25) :5375-5388

[9] Angiogenesis: the role of the microenvironment in flipping the switch [J].

Giordano, FJ ;

Johnson, RS .

CURRENT OPINION IN GENETICS & DEVELOPMENT, 2001, 11 (01) :35-40

[10]

HIRST GC, 2003, Patent No. 153752